AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and ...
NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
4d
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment ...
In this secondary analysis of the ECOG-ACRIN E2906 study, researchers assessed vulnerabilities of AML patients aged 60 years or older and their affect on survival outcomes.
Hosted on MSN
What To Know About Acute Myelogenous Leukemia (AML)
Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a type of cancer that starts in your bone marrow (the soft, spongy tissue inside the bones that makes blood cells). AML is ...
The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging to treat. While advances in immunotherapy have cured many patients with other blood cancers, ...
The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
3d
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement
SELLAS Life Sciences Group (SLS) has entered an agreement with IMPACT-AML, a pan-European clinical network, to run a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback